Obesity (BASKET)

LE WE PMID CA

Obesity (BASKET)

Adipositas (allg)

11 beta HSD1

2 Arachidonoylglycerol

A Zip F1 mouse

Adipokine

Adiponectin

Adipose tissue (BASKET)

Adipose tissue (Development)

Agouti

AGRP neuron

AMP activated protein kinase

Anandamide

Androgens (Hypogonadism)

Angiopoietin like factors

ANGPTL2

ANGPTL6

Anorexia nervosa

Arcuate nucleus

Arterial hypertension (BASKET)

Atherosclerosis (BASKET)

Autoantibodies Anti Melanocortin 4 receptor

Autophagy

Bariatric surgery

Cachexia (Oncology and BASKET)

Cardiovascular risk

Carnitine palmitoyltransferase deficiency

Cholecystokinin

Circadian clock

CNS (Deep brain stimulation)

Conjugated linoleic acid

Db mouse

Developmental origin of disease

Diabetes mellitus (BASKET)

Diabetes mellitus (Beta cell decay)

Dorsomedial nucleus

Drug development

DsbA L

Endocannabinoid

Endocrine disruptor

Energy expenditure

ERS UFR (Diseases)

Estrogen

Exercise (Physiology)

Eye (Diseases)

FABP1 L FABP

Fatty acids (Free)

Fructose

Genetics (Imprinting)

Ghrelin

GNAS

GnRH

Growth hormone

IAPP islet amyloid polypeptide

IGF1

IKKbeta

Inflammation (BASKET)

Inflammation homeostatic

Inflammation resolution

Insulin (resistance)

Interleukin15

Interleukin17

Ion channel (Sodium ENaC)

Ion channel (Sodium)

Kidney (Chronic renal failure)

Kisspeptin

Koletsky rat

Krox20 Egr2

Leptin

Liddle s syndrome

Lipoprotein (HDL)

Lipoxin

Liver (Steatohepatosis)

Lorcaserin

Macrophages

Metabolic syndrome

Metformin

MIF

Muscle (Physiology)

Neoplasia (Cancer survivor)

Neoplasia (Carcinogenesis)

Neoplasia (Tumor biology and immunology)

Neuropeptide Y

Nhlh2

NR1C1 PPAR alpha

Nutrition (Neuroendocrinology)

ob ob mouse

Obesity (BASKET)

Obesogen

Orlistat

Osteoporosis

Otsuka Long Evans Tokushima fatty rat OLETF rat

Paraventricular nuclei

PGC1alpha

Phentermine

Prader Willi syndrome

Prostaglandin D2

Protectin

Protein kinase R

RBP4

Receptor (Interleukin6 GP130)

Resistin

Resolvin

Reward (Neurophysiology)

Rimonabant

RMI1

Sibutramine

SIRT1

Sleep disorder

SOCS3

STAT3

Topiramate

TRPV1

TRPV4

Tubby mouse

UCP1

Ventromedial nucleus

Visfatin

Zucker rat

2006 1	The medical complications of obesity. [16916862] QJM 99(9): 565-79 (2006)
2006 2	Preventing and managing pediatric obesity. Recommendations for family physicians. [16572577] Can Fam Physician 52(): 322-8 (2006)
2007 3	Obesity in children. [19454076] Clin Evid (Online) 2007(): (2007)
2008 4	Orlistat in the prevention of diabetes in the obese patient. [18561508] Vasc Health Risk Manag 4(2): 325-36 (2008)
2006 5	Vascular risks and management of obesity in children and adolescents. [17319462] Vasc Health Risk Manag 2(2): 171-87 (2006)
2007 6	Pharmacological treatment of the overweight patient. [17540905] Pharmacol Rev 59(2): 151-84 (2007)
2008 7	Atherogenic lipid risk factors in men classified as overweight and obese according to the preliminary WHO guidelines for Asians. [19130868] Indian J Physiol Pharmacol 52(2): 205-8 (2008)
2009 8	The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. [19726018] Health Technol Assess 13(41): 1-190, 215-357, iii-iv (2009)
2008 9	Obesity: a review of pathogenesis and management strategies. [18209783] Can J Gastroenterol 22(1): 61-8 (2008)
2004 10	Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. [15051594] Am J Clin Nutr 79(4): 537-43 (2004)
1993 11	Mechanisms by which somatotropin decreases adipose tissue growth. [8328402] Am J Clin Nutr 58(2 Suppl): 287S-295S (1993)
1992 12	The role of very-low-calorie diets in obesity. [1615890] Am J Clin Nutr 56(1 Suppl): 240S-243S (1992)
1992 13	Pathophysiology of obesity. [1733117] Am J Clin Nutr 55(2 Suppl): 488S-494S (1992)
1992 14	A brief overview of human energy metabolism and its relationship to essential obesity. [1728837] Am J Clin Nutr 55(1 Suppl): 242S-245S (1992)
1979 15	Obesity: adverse effects on health and longevity. [389027] Am J Clin Nutr 32(12 Suppl): 2723-33 (1979)
2001 16	Infectobesity: obesity of infectious origin. [11584109] J Nutr 131(10): 2794S-2797S (2001)
2005 17	Obesity: prevalence, theories, medical consequences, management, and research directions. [18500955] J Int Soc Sports Nutr 2(): 4-31 (2005)
2004 18	Monogenic human obesity syndromes. [14749512] Recent Prog Horm Res 59(): 409-24 (2004)
2004 19	Hypertension and obesity. [14749502] Recent Prog Horm Res 59(): 169-205 (2004)
2010 20	Deep brain stimulation compared with bariatric surgery for the treatment of morbid obesity: a decision analysis study. [20672917] Neurosurg Focus 29(2): E15 (2010)
2008 21	Adverse renal consequences of obesity. [18234955] Am J Physiol Renal Physiol 294(4): F685-96 (2008)
2005 22	Meta-analysis: surgical treatment of obesity. [15809466] Ann Intern Med 142(7): 547-59 (2005)
2005 23	Meta-analysis: pharmacologic treatment of obesity. [15809465] Ann Intern Med 142(7): 532-46 (2005)
2008 24	Association between depressive symptoms in childhood and adolescence and overweight in later life: review of the recent literature. [18838652] Arch Pediatr Adolesc Med 162(10): 981-8 (2008)
2005 25	Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. [15837955] Circulation 111(15): 1999-2012 (2005)
2007 26	Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. [17699463] Clin J Am Soc Nephrol 2(3): 550-62 (2007)
2008 27	Neurophysiological pathways to obesity: below awareness and beyond individual control. [18586908] Diabetes 57(7): 1768-73 (2008)
2006 28	Influence of obesity on the risk of developing colon cancer. [16239255] Gut 55(2): 285-91 (2006)
2004 29	New thoughts on managing obesity. [15194659] Gut 53(7): 1044-53 (2004)
2008 30	Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. [18782881] J Clin Endocrinol Metab 93(12): 4600-5 (2008)
2008 31	Clinical review: behavioral interventions to prevent childhood obesity: a systematic review and metaanalyses of randomized trials. [18782880] J Clin Endocrinol Metab 93(12): 4606-15 (2008)
2008 32	Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. [18782869] J Clin Endocrinol Metab 93(12): 4576-99 (2008)
2008 33	Obesity-associated liver disease. [18987273] J Clin Endocrinol Metab 93(11 Suppl 1): S74-80 (2008)
2008 34	Adipocytokines and the metabolic complications of obesity. [18987272] J Clin Endocrinol Metab 93(11 Suppl 1): S64-73 (2008)
2008 35	Obesity in children and adolescents. [18987268] J Clin Endocrinol Metab 93(11 Suppl 1): S31-6 (2008)
2008 36	Update on obesity. [18539769] J Clin Endocrinol Metab 93(6): 2027-34 (2008)
2007 37	Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. [17148564] J Clin Endocrinol Metab 92(2): 386-95 (2007)
2005 38	Childhood obesity. [15598688] J Clin Endocrinol Metab 90(3): 1871-87 (2005)
2004 39	Childhood obesity. [15356008] J Clin Endocrinol Metab 89(9): 4211-8 (2004)
2004 40	Medical consequences of obesity. [15181027] J Clin Endocrinol Metab 89(6): 2583-9 (2004)
2001 41	Obesity-related glomerulopathy: an emerging epidemic. [11260414] Kidney Int 59(4): 1498-509 (2001)
2007 42	Evaluation and management of childhood and adolescent obesity. [17908531] Mayo Clin Proc 82(10): 1258-64 (2007)
2007 43	Viruses as an etiology of obesity. [17908526] Mayo Clin Proc 82(10): 1192-8 (2007)
2007 44	Surgery for morbid obesity. [17267672] Postgrad Med J 83(975): 8-15 (2007)
1988 45	Obesity. Part II--Treatment. [3074556] West J Med 149(5): 555-71 (1988)
1988 46	Obesity. Part I--Pathogenesis. [3067447] West J Med 149(4): 429-41 (1988)
2007 47	Diseases associated with childhood obesity. [17377057] AJR Am J Roentgenol 188(4): 1118-30 (2007)
2007 48	Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. [17420493] CMAJ 176(8): 1103-6 (2007)
2007 49	2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. [17420481] CMAJ 176(8): S1-13 (2007)
2008 50	The role of SOCS-3 protein in leptin resistance and obesity. [18560028] Acta Med Indones 40(2): 89-95 (2008)
2009 51	Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. [19299892] Am J Nephrol 30(2): 140-6 (2009)
2011 52	Respiratory complications of obesity. [21458904] Arch Bronconeumol 47(5): 252-61 (2011)
2004 53	Dietary supplements for body-weight reduction: a systematic review. [15051593] Am J Clin Nutr 79(4): 529-36 (2004)
2005 54	Survival advantages of obesity in dialysis patients. [15755821] Am J Clin Nutr 81(3): 543-54 (2005)
2006 55	Metabolic programming: fetal origins of obesity and metabolic syndrome in the adult. [16638823] Am J Physiol Endocrinol Metab 291(3): E439-40 (2006)
2006 56	ABC of obesity. Assessment of obesity and its clinical implications. [17008674] BMJ 333(7570): 695-8 (2006)
2006 57	ABC of obesity. Management: Part I--behaviour change, diet, and activity. [17023467] BMJ 333(7571): 740-3 (2006)
2006 58	ABC of obesity. Management: Part III--surgery. [17068036] BMJ 333(7574): 900-3 (2006)
2006 59	ABC of obesity. Management: part II--drugs. [17038738] BMJ 333(7572): 794-7 (2006)
2006 60	ABC of obesity. Strategies for preventing obesity. [17082548] BMJ 333(7575): 959-62 (2006)
2006 61	ABC of obesity. Obesity and cancer. [17124223] BMJ 333(7578): 1109-11 (2006)
2006 62	ABC of obesity: obesity and vascular disease. [17110725] BMJ 333(7577): 1060-3 (2006)
2006 63	ABC of obesity. Risk factors for diabetes and coronary heart disease. [17095784] BMJ 333(7576): 1009-11 (2006)
2006 64	ABC of obesity. Childhood obesity. [17158388] BMJ 333(7580): 1207-10 (2006)
2006 65	ABC of obesity. Obesity and reproduction. [17138998] BMJ 333(7579): 1159-62 (2006)
2009 66	Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. [19348861] Biochim Biophys Acta 1793(7): 1128-43 (2009)
2006 67	Tending to the musculoskeletal problems of obesity. [16970135] Cleve Clin J Med 73(9): 839-45 (2006)
2003 68	Prevention of pediatric overweight and obesity. [12897303] Pediatrics 112(2): 424-30 (2003)
2007 69	Assessment of child and adolescent overweight and obesity. [18055652] Pediatrics 120 Suppl 4(-): S193-228 (2007)
2007 70	Recommendations for prevention of childhood obesity. [18055653] Pediatrics 120 Suppl 4(-): S229-53 (2007)
2007 71	Recommendations for treatment of child and adolescent overweight and obesity. [18055654] Pediatrics 120 Suppl 4(-): S254-88 (2007)
2009 72	Spectrum and management of hypertriglyceridemia among children in clinical practice. [19171610] Pediatrics 123(2): 458-65 (2009)
2007 73	Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. [17659704] World J Gastroenterol 13(26): 3540-53 (2007)
2007 74	Treatment of obesity. [17285790] Mayo Clin Proc 82(1): 93-101; quiz 101-2 (2007)
2007 75	Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. [17699878] Physiology (Bethesda) 22(-): 252-60 (2007)
2010 76	Sympathetic activation in obesity: a noninnocent bystander. [20625071] Hypertension 56(3): 338-40 (2010)
2002 77	Obesity hypertension in children: a problem of epidemic proportions. [12364344] Hypertension 40(4): 441-7 (2002)
2010 78	Obesity, sympathetic overdrive, and hypertension: the leptin connection. [20194295] Hypertension 55(4): 844-5 (2010)
2007 79	Hypoadiponectinemia: a novel link between obesity and hypertension? [17452503] Hypertension 49(6): 1217-9 (2007)
2008 80	Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? [18086947] Hypertension 51(2): 168-71 (2008)
2004 81	Overview: obesity: what does it have to do with kidney disease? [15504929] J Am Soc Nephrol 15(11): 2768-72 (2004)
2004 82	Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? [15504931] J Am Soc Nephrol 15(11): 2775-91 (2004)
2004 83	The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. [15504932] J Am Soc Nephrol 15(11): 2792-800 (2004)
2003 84	After all those fat years: renal consequences of obesity. [14605265] Nephrol Dial Transplant 18(12): 2471-4 (2003)
2008 85	Why is obesity associated with osteoarthritis? Insights from mouse models of obesity. [18836239] Biorheology 45(3-4): 387-98 (2008)
2010 86	Endoplasmic reticulum stress and inflammation in obesity and diabetes. [20814028] Circ Res 107(5): 579-91 (2010)
2007 87	Cardiac energy metabolism in obesity. [17702980] Circ Res 101(4): 335-47 (2007)
2007 88	Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. [17615379] Circ Res 101(1): 27-39 (2007)
2007 89	Leptin signaling and obesity: cardiovascular consequences. [17872473] Circ Res 101(6): 545-59 (2007)
2011 90	Biology of obesity: lessons from animal models of obesity. [21274264] J Biomed Biotechnol 2011(-): 197636 (2011)
2006 91	Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. [16627822] Arterioscler Thromb Vasc Biol 26(5): 968-76 (2006)
2010 92	Epithelial Na+ channel (ENaC), hormones, and hypertension. [20460373] J Biol Chem 285(31): 23527-31 (2010)
2010 93	The possible role of IL-17 in obesity-associated cancer. [21103795] ScientificWorldJournal 10(-): 2265-71 (2010)
2010 94	Resolution of adipose tissue inflammation. [20454765] ScientificWorldJournal 10(-): 832-56 (2010)
2006 95	Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. [16874931] Philos Trans R Soc Lond B Biol Sci 361(1471): 1159-85 (2006)
2006 96	Genetics of obesity. [16815794] Philos Trans R Soc Lond B Biol Sci 361(1471): 1095-105 (2006)
2008 97	Role of body fat distribution and the metabolic complications of obesity. [18987271] J Clin Endocrinol Metab 93(11 Suppl 1): S57-63 (2008)
2008 98	Lifestyle and pharmacological approaches to weight loss: efficacy and safety. [18987274] J Clin Endocrinol Metab 93(11 Suppl 1): S81-8 (2008)
2008 99	Bariatric surgery: risks and rewards. [18987275] J Clin Endocrinol Metab 93(11 Suppl 1): S89-96 (2008)
2009 100	Melanocortin-4-receptor autoantibodies: a new player in obesity. [19261898] J Clin Endocrinol Metab 94(3): 757-9 (2009)
2010 101	Homeostatic inflammation, an emerging concept. [20823624] Endocr J 57(8): 657-8 (2010)
2008 102	Obesity and free fatty acids. [18775356] Endocrinol Metab Clin North Am 37(3): 635-46, viii-ix (2008)
2009 103	Pediatric obesity: etiology and treatment. [19717003] Endocrinol Metab Clin North Am 38(3): 525-48 (2009)
2010 104	Metabolism and circadian rhythms--implications for obesity. [19854863] Endocr Rev 31(1): 1-24 (2010)
2011 105	Ghrelin biology and its role in weight-related disorders. [21712018] Discov Med 11(61): 521-8 (2011)
2011 106	Genetic approaches to understanding human obesity. [21633175] J Clin Invest 121(6): 2080-6 (2011)
2011 107	Adipose tissue remodeling and obesity. [21633177] J Clin Invest 121(6): 2094-101 (2011)
2011 108	Inflammatory links between obesity and metabolic disease. [21633179] J Clin Invest 121(6): 2111-7 (2011)
2010 109	Metabolic effects of fructose and the worldwide increase in obesity. [20086073] Physiol Rev 90(1): 23-46 (2010)
2008 110	Cardiac remodeling in obesity. [18391168] Physiol Rev 88(2): 389-419 (2008)
2010 111	JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. [20371626] FASEB J 24(8): 2596-611 (2010)
2007 112	The obesity-cancer link: lessons learned from a fatless mouse. [17363554] Cancer Res 67(6): 2391-3 (2007)
2006 113	Obesity in childhood and adolescence: evidence based clinical and public health perspectives. [16822919] Postgrad Med J 82(969): 429-37 (2006)
2003 114	Principles and practices in the management of obesity. [12888610] Am J Respir Crit Care Med 168(3): 274-80 (2003)
2006 115	Pharmacological treatment of obesity. [16767304] Arq Bras Endocrinol Metabol 50(2): 377-89 (2006)
2009 116	Genetic variants influencing effectiveness of weight loss strategies. [19466204] Arq Bras Endocrinol Metabol 53(2): 129-38 (2009)
2009 117	Translational research into gut microbiota: new horizons in obesity treatment. [19466205] Arq Bras Endocrinol Metabol 53(2): 139-44 (2009)
2009 118	The brain is the conductor: diet-induced inflammation overlapping physiological control of body mass and metabolism. [19466207] Arq Bras Endocrinol Metabol 53(2): 151-8 (2009)
2009 119	Infeccions as the etiology for obesity. [19466208] Arq Bras Endocrinol Metabol 53(2): 159-64 (2009)
2009 120	Impact of adiposity on immunological parameters. [19466211] Arq Bras Endocrinol Metabol 53(2): 183-9 (2009)
2009 121	Adiposity in childhood cancer survivors: insights into obesity physiopathology. [19466212] Arq Bras Endocrinol Metabol 53(2): 190-200 (2009)
2009 122	Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. [19466213] Arq Bras Endocrinol Metabol 53(2): 201-12 (2009)
2009 123	Epidemiological and molecular mechanisms aspects linking obesity and cancer. [19466214] Arq Bras Endocrinol Metabol 53(2): 213-26 (2009)
2009 124	Metabolic disturbances linked to obesity: the role of impaired tissue perfusion. [19466216] Arq Bras Endocrinol Metabol 53(2): 238-45 (2009)
2009 125	Management of obesity in adolescents: state of art. [19466218] Arq Bras Endocrinol Metabol 53(2): 252-61 (2009)
2009 126	The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. [19466219] Arq Bras Endocrinol Metabol 53(2): 262-70 (2009)
2009 127	Emerging drugs for obesity therapy. [19466220] Arq Bras Endocrinol Metabol 53(2): 271-80 (2009)
2011 128	Bariatric surgery. [21655459] Dtsch Arztebl Int 108(20): 341-6 (2011)
2006 129	The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. [16636330] CMAJ 174(9): 1293-9 (2006)
2004 130	10: Management of obesity. [15115430] Med J Aust 180(9): 474-80 (2004)
2011 131	The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. [21247515] Health Technol Assess 15(2): 1-182 (2011)
2009 132	Rimonabant for the treatment of overweight and obese people. [19846024] Health Technol Assess 13 Suppl 3(-): 13-22 (2009)
2009 133	Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. [19443932] Pharmacol Rep 61(2): 217-24 (2009)
2007 134	Adolescent overweight and obesity--how best to manage in the general practice setting. [17676183] Aust Fam Physician 36(8): 606-12 (2007)
2010 135	Obesity in children & adolescents. [21150012] Indian J Med Res 132(5): 598-607 (2010)
2010 136	The adverse effects of obesity on conception and implantation. [20395425] Reproduction 140(3): 347-64 (2010)
2007 137	Developmental programming of obesity in mammals. [17170060] Exp Physiol 92(2): 287-98 (2007)
2005 138	The neurobiology of human obesity. [16105936] Exp Physiol 90(5): 673-82 (2005)
2005 139	Role of leptin in obesity-related hypertension. [16105937] Exp Physiol 90(5): 683-8 (2005)
2009 140	Medical management of obesity and its complications. [19221667] Ann Acad Med Singapore 38(1): 22-7 (2009)
2009 141	Endocrine disrupters as obesogens. [19433244] Mol Cell Endocrinol 304(1-2): 19-29 (2009)
2009 142	Effects of bisphenol A on adipokine release from human adipose tissue: Implications for the metabolic syndrome. [19433247] Mol Cell Endocrinol 304(1-2): 49-54 (2009)
2010 143	Hormones and cytokines in childhood obesity. [21048235] Indian Pediatr 47(10): 829-39 (2010)
2010 144	Mediators of inflammation in obesity and its comorbidities. [20885924] Mediators Inflamm 2010(-): - (2010)
2010 145	The role of adipose tissue and adipokines in obesity-related inflammatory diseases. [20671929] Mediators Inflamm 2010(-): 802078 (2010)
2010 146	Chronic inflammation in obesity and the metabolic syndrome. [20706689] Mediators Inflamm 2010(-): - (2010)
2010 147	Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. [20508742] Mediators Inflamm 2010(-): 219583 (2010)
2010 148	Functional food targeting the regulation of obesity-induced inflammatory responses and pathologies. [20508825] Mediators Inflamm 2010(-): 367838 (2010)
2010 149	Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. [20508843] Mediators Inflamm 2010(-): 513948 (2010)
2010 150	Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. [20652043] Mediators Inflamm 2010(-): 174341 (2010)
2010 151	Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients. [20224654] Mediators Inflamm 2010(-): 364957 (2010)
2010 152	Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. [20169173] Mediators Inflamm 2010(-): 610479 (2010)
2008 153	Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. [18401346] Nat Rev Mol Cell Biol 9(5): 367-77 (2008)
2011 154	The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. [21177942] J Exp Biol 214(Pt 2): 206-29 (2011)
2005 155	Surgical management of morbid obesity. [15677820] Diabetes Care 28(2): 475-80 (2005)
2007 156	Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. [17259519] Diabetes Care 30(2): 395-402 (2007)
2009 157	Metformin for obesity in children and adolescents: a systematic review. [19502540] Diabetes Care 32(9): 1743-5 (2009)
2008 158	Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. [18227491] Diabetes Care 31 Suppl 2(-): S229-40 (2008)
2009 159	Minireview: Endocannabinoids and their receptors as targets for obesity therapy. [19372200] Endocrinology 150(6): 2531-6 (2009)
2010 160	Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. [20707765] Expert Rev Cardiovasc Ther 8(12): 1777-801 (2010)
2011 161	Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. [21438803] Expert Rev Cardiovasc Ther 9(3): 265-77 (2011)
2009 162	Unraveling the paradoxical link between obesity and heart failure: the role of adipocytokines. [19379057] Expert Rev Cardiovasc Ther 7(4): 337-40 (2009)
2008 163	Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. [18327995] Expert Rev Cardiovasc Ther 6(3): 343-68 (2008)
2010 164	Scope and mechanisms of obesity-related renal disease. [20134323] Curr Opin Nephrol Hypertens 19(3): 227-34 (2010)
2010 165	Autophagy: roles in obesity-induced ER stress and adiponectin downregulation in adipocytes. [20864818] Autophagy 6(8): 1196-7 (2010)
2010 166	Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. [20144759] Cell 140(3): 338-48 (2010)
2008 167	Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. [18854155] Cell 135(1): 61-73 (2008)
2010 168	Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. [20519119] Cell Metab 11(6): 467-78 (2010)
2009 169	Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. [19356714] Cell Metab 9(4): 327-38 (2009)
2008 170	The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. [18436717] Clin Chem 54(6): 945-55 (2008)
2009 171	Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation? [19246600] Diabetes 58(3): 518-9 (2009)
2009 172	Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress. [19151199] Diabetes 58(4): 906-16 (2009)
2010 173	Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. [20534724] Endocrinology 151(8): 3577-88 (2010)
2009 174	Pharmacotherapy for obesity. [20002075] Br J Clin Pharmacol 68(6): 804-10 (2009)
2009 175	Recent progress in the genetics of common obesity. [20002076] Br J Clin Pharmacol 68(6): 811-29 (2009)
2009 176	Obesity treatment: novel peripheral targets. [20002077] Br J Clin Pharmacol 68(6): 830-43 (2009)
2009 177	New central targets for the treatment of obesity. [20002079] Br J Clin Pharmacol 68(6): 852-60 (2009)
2011 178	The use of serotonergic drugs to treat obesity--is there any hope? [21448447] Drug Des Devel Ther 5(-): 95-109 (2011)
2008 179	Adipose tissue inflammation and liver pathology in human obesity. [19195627] Diabetes Metab 34(6 Pt 2): 658-63 (2008)
2009 180	Role of macrophage tissue infiltration in obesity and insulin resistance. [19539513] Diabetes Metab 35(4): 251-60 (2009)
2010 181	Role of histone methylation and demethylation in adipogenesis and obesity. [20592862] Organogenesis 6(1): 24-32 (2010)
2008 182	TRPV1-null mice are protected from diet-induced obesity. [18503767] FEBS Lett 582(15): 2257-62 (2008)
2012 183	TRPV4 deficiency increases skeletal muscle metabolic capacity and resistance against diet-induced obesity. [22207724] J Appl Physiol 112(7): 1223-32 (2012)
2004 184	Surgical treatment of obesity: a review. [14746355] J Natl Med Assoc 96(1): 61-75 (2004)
2008 185	Cause and effect in childhood obesity: solutions for a national epidemic. [18948638] J Am Osteopath Assoc 108(10): 545-52 (2008)
2009 186	How physician obesity specialists use drugs to treat obesity. [19300434] Obesity (Silver Spring) 17(9): 1730-5 (2009)
2009 187	The stigma of obesity: a review and update. [19165161] Obesity (Silver Spring) 17(5): 941-64 (2009)
2008 188	Obesity-related changes in high-density lipoprotein metabolism. [18388903] Obesity (Silver Spring) 16(6): 1152-60 (2008)
2008 189	Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. [18464753] Obesity (Silver Spring) 16(6): 1161-77 (2008)
2006 190	Leptin resistance and obesity. [17021377] Obesity (Silver Spring) 14 Suppl 5(-): 254S-258S (2006)
2011 191	Current and future drug targets in weight management. [21181547] Pharm Res 28(8): 1792-818 (2011)
2008 192	Effectiveness of weight management programs in children and adolescents. [19408967] Evid Rep Technol Assess (Full Rep) -(170): 1-308 (2008)
2011 193	Pharmacological treatment of obesity: a public health perspective. [21519691] Cad Saude Publica 27(3): 405, 404 (2011)
2008 194	Childhood and adolescent obesity and adult mortality: a systematic review of cohort studies. [18797731] Cad Saude Publica 24 Suppl 4(-): s558-68 (2008)
2011 195	The gp130 receptor cytokine family: regulators of adipocyte development and function. [21375496] Curr Pharm Des 17(4): 340-6 (2011)
2010 196	Cellular bioenergetics as a target for obesity therapy. [20514071] Nat Rev Drug Discov 9(6): 465-82 (2010)
2011 197	Toward a more complete (and less controversial) understanding of energy expenditure and its role in obesity pathogenesis. [21193735] Diabetes 60(1): 17-23 (2011)
2009 198	SIRT1 genetic variation is related to BMI and risk of obesity. [19741164] Diabetes 58(12): 2828-34 (2009)
2007 199	New agents in development for the management of obesity. [17850307] Int J Clin Pract 61(12): 2103-12 (2007)
2010 200	Childhood obesity. [20451244] Lancet 375(9727): 1737-48 (2010)
2011 201	Hedonic and incentive signals for body weight control. [21340584] Rev Endocr Metab Disord 12(3): 141-51 (2011)
2011 202	Predictors of weight loss and maintenance in patients treated with antiobesity drugs. [21792322] Diabetes Metab Syndr Obes 4(-): 229-43 (2011)
2010 203	Tackling obesity: new therapeutic agents for assisted weight loss. [21437080] Diabetes Metab Syndr Obes 3(-): 95-112 (2010)
2010 204	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents. [21437083] Diabetes Metab Syndr Obes 3(-): 125-43 (2010)
2010 205	Active video games to promote physical activity in children and youth: a systematic review. [20603468] Arch Pediatr Adolesc Med 164(7): 664-72 (2010)
2009 206	The role of the sympathetic nervous system in obesity-related hypertension. [19442330] Curr Hypertens Rep 11(3): 206-11 (2009)
2008 207	Putative environmental-endocrine disruptors and obesity: a review. [18769210] Curr Opin Endocrinol Diabetes Obes 15(5): 403-8 (2008)
2009 208	Obesity and kidney cancer risk in men: a meta-analysis (1992-2008). [19537897] Asian Pac J Cancer Prev 10(2): 279-86 (2009)
2009 209	The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. [19320986] BMC Public Health 9(-): 88 (2009)
2010 210	Metabolic effects of obesity: A review. [21537431] World J Diabetes 1(3): 76-88 (2010)
2005 211	Emerging pharmacological approaches to the treatment of obesity. [16124937] J Pharm Pharm Sci 8(2): 259-71 (2005)
2010 212	From monogenic to polygenic obesity: recent advances. [20127379] Eur Child Adolesc Psychiatry 19(3): 297-310 (2010)
2008 213	UCP1: its involvement and utility in obesity. [19136989] Int J Obes (Lond) 32 Suppl 7(-): S32-8 (2008)
2008 214	Inflammation and endoplasmic reticulum stress in obesity and diabetes. [19136991] Int J Obes (Lond) 32 Suppl 7(-): S52-4 (2008)
2010 215	The role of GNAS and other imprinted genes in the development of obesity. [19844212] Int J Obes (Lond) 34(1): 6-17 (2010)
2007 216	Obesity and eye diseases. [17355856] Surv Ophthalmol 52(2): 180-95 (2007)
2011 217	AMPK as Target for Intervention in Childhood and Adolescent Obesity. [21318055] J Obes 2011(-): 252817 (2011)
2011 218	Is there a metabolic program in the skeletal muscle of obese individuals? [21603262] J Obes 2011(-): 250496 (2011)
2008 219	Nhlh2: a basic helix-loop-helix transcription factor controlling physical activity. [18815487] Exerc Sport Sci Rev 36(4): 187-92 (2008)
2010 220	Behavioral and pharmacologic therapies for obesity. [20680034] Nat Rev Endocrinol 6(10): 578-88 (2010)
2009 221	Central leptin receptor action and resistance in obesity. [20029269] J Investig Med 57(7): 789-94 (2009)
2002 222	Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. [11850760] Int J Obes Relat Metab Disord 26(2): 262-73 (2002)
2009 223	Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. [19389060] Obes Rev 10(3): 333-41 (2009)
2009 224	The medical risks of obesity. [19940414] Postgrad Med 121(6): 21-33 (2009)
2007 225	A systematic review of environmental correlates of obesity-related dietary behaviors in youth. [16861362] Health Educ Res 22(2): 203-26 (2007)
2010 226	Association of endocrine disruptors and obesity: perspectives from epidemiological studies. [20113374] Int J Androl 33(2): 324-32 (2010)
2008 227	Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. [17784844] J Bone Miner Res 23(1): 17-29 (2008)
2010 228	Adipose tissue-derived progenitor cells and cancer. [21607127] World J Stem Cells 2(5): 103-13 (2010)
2010 229	Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. [20628262] Neuroendocrinology 91(4): 302-7 (2010)
2008 230	Meta-analysis of short sleep duration and obesity in children and adults. [18517032] Sleep 31(5): 619-26 (2008)
2011 231	Molecular basis of obesity: current status and future prospects. [22043164] Curr Genomics 12(3): 154-68 (2011)
2011 232	Prader-Willi Syndrome: Obesity due to Genomic Imprinting. [22043168] Curr Genomics 12(3): 204-15 (2011)
2009 233	Minireview: the case for obesogens. [19372238] Mol Endocrinol 23(8): 1127-34 (2009)
2011 234	Anti-ghrelin vaccine for obesity: a feasible alternative to dieting? [21988299] Expert Rev Vaccines 10(10): 1363-5 (2011)
2011 235	New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. [21988829] Lipids Health Dis 10(-): 176 (2011)
2010 236	GH/IGF-I regulation in obesity--mechanisms and practical consequences in children and adults. [20197666] Horm Res Paediatr 73(3): 153-60 (2010)
2009 237	Leptin resistance: a prediposing factor for diet-induced obesity. [19091915] Am J Physiol Regul Integr Comp Physiol 296(3): R493-500 (2009)
2008 238	Intramuscular lipid oxidation and obesity. [18256136] Am J Physiol Regul Integr Comp Physiol 294(4): R1111-6 (2008)
2008 239	Complex genetics of obesity in mouse models. [18435591] Annu Rev Nutr 28(-): 331-45 (2008)
2009 240	Adipose tissue: a motor for the inflammation associated with obesity. [19319966] IUBMB Life 61(4): 424-30 (2009)
2008 241	Interleukin-15: a muscle-derived cytokine regulating fat-to-lean body composition. [17709786] J Anim Sci 86(14 Suppl): E75-83 (2008)
2007 242	Obesity, diet and risk of non-Hodgkin lymphoma. [17337642] Cancer Epidemiol Biomarkers Prev 16(3): 392-5 (2007)
2004 243	Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. [14749510] Recent Prog Horm Res 59(-): 359-93 (2004)
2007 244	Developmental exposure to endocrine disruptors and the obesity epidemic. [17321108] Reprod Toxicol 23(3): 290-6 (2007)
2010 245	Liver fatty acid-binding protein and obesity. [20537520] J Nutr Biochem 21(11): 1015-32 (2010)
2010 246	Antiobesity mechanisms of action of conjugated linoleic acid. [19954947] J Nutr Biochem 21(3): 171-9 (2010)
2011 247	Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. [21892560] Nutr Hosp 26(3): 451-7 (2011)
2010 248	Is NAD(P)H oxidase a missing link for air pollution-enhanced obesity? [21084700] Arterioscler Thromb Vasc Biol 30(12): 2323-4 (2010)
2010 249	The use of lorcaserin in the management of obesity: a critical appraisal. [21267355] Drug Des Devel Ther 5(): 1-7 (2010)
2011 250	Adipocyte hyperplasia and RMI1 in the treatment of obesity. [21199368] FEBS J 278(4): 565-9 (2011)
2011 251	Hypothalamic malonyl-CoA and CPT1c in the treatment of obesity. [21199367] FEBS J 278(4): 552-8 (2011)
2011 252	Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. [21182596] FEBS J 278(4): 559-64 (2011)
PMC 253	Therapy of obese patients with cardiovascular disease. [23332347] Curr Opin Pharmacol 13(2):200-4 (2013)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Obesity (BASKET).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Obesity (BASKET).php on line 92